PARIS, Sept. 24, 2020 /PRNewswire/ -- Rarecells Diagnostics [http://www.rarecells.com/] (France), a leading liquid biopsy company, is pleased to announce that the University Medical Center of Groningen, The Netherlands, has published research comparing the performance of the ISET® technology to the reference antibody-based system in Non-Small Cells Lung Cancer (NSCLC) demonstrating key advantages of the ISET® technology.
Antibody-based systems are known to underperform for isolating Circulating Tumor Cells (CTC) due to low or lack of markers expression in critical subsets of CTC.
The marker-independent ISET® technology has already been shown to detect CTC from NSCLC with unparalleled sensitivity and specificity, prior to imaging. However, CTC rarity in usual blood draw volumes can prevent extensive CTC analyses and culture.
Diagnostic leukapheresis (DLA) is a robust process that concentrates mononuclear cells, including CTC, from the whole blood volume of an individual. Antibody-based systems face significant challenges in isolating CTC from billions of white blood cells present in DLA volumes.
The work of Dr. Tamminga, published in the peer-reviewed journal Cancers [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226321/], demonstrates that CTC can be efficiently isolated from large DLA volumes with the ISET® technology. These results solve the critical issue of CTC rarity and pave the way for their use in early diagnostics of cancer, prognostics, theranostics, and in vitro personalized drug efficacy tests, including through CTC culture.
"With the ISET® technology, we were able to effectively extract CTC in higher numbers and from larger DLA volumes, in all cases thus increasing sensitivity for further studies of CTC in NSCLC patients," said Dr. Menno Tamminga.
Davide Brechot, Deputy Director and CTO of Rarecells Diagnostics commented: "Dr. Tamminga's publication demonstrates the exceptional performance of the ISET® technology to harvest CTC from DLA products. It opens the way to new CTC-based approaches to treat and follow-up patients with NSCLC and with other types of cancers. These results add to the body of published evidence on ISET® technology's excellence."
ISET® has been validated by more than 85 independent scientific publications on over 3,400 cancer patients and more than 1,200 cancer-free individuals. It demonstrates unparalleled performance for the isolation and characterization of individual CTC and CTC clusters.
Rarecells Diagnostics is the exclusive licensee of the ISET® patent portfolios owned by University of Paris, INSERM and Assistance Publique-Hôpitaux de Paris (AP-HP). The company develops high value, innovative diagnostic tests in the fields of liquid biopsy and early cancer diagnostics.
Logo - https://mma.prnewswire.com/media/1280816/Rarecells_Diagnostics_Logo.jpg [https://mma.prnewswire.com/media/1280816/Rarecells_Diagnostics_Logo.jpg]
Contact: firstname.lastname@example.org [mailto:email@example.com]
CONTACT: +33 (0)1 40 61 56 01